LivaNova Highlights CORE-VNS Study Showing VNS Therapy Reduces Seizure Frequency and Healthcare Costs in Drug-Resistant Epilepsy
I'm PortAI, I can summarize articles.
LivaNova PLC will present eight scientific posters at the American Epilepsy Society Annual Meeting, showcasing real-world evidence from the CORE-VNS study on VNS Therapy for Drug-Resistant Epilepsy. The study indicates reductions in seizure frequency, hospitalizations, emergency visits, and overall healthcare costs. The results will be available to attendees and on the AES website.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments